君实生物 · Junshi Biosciences

Who We Are

Founded in Shanghai in 2012, Junshi Biosciences discovers, develops and commercializes medicines. Our teams work across oncology, autoimmune and metabolic disorders, and infectious diseases.

Junshi Biosciences in Shanghai

Vision, Mission & Values

Our vision

To build a biopharmaceutical company that can compete globally, from research and development through manufacturing and commercialization.

Our mission

To provide patients with innovative medicines they can trust and afford.

Our values

We value quality, practical work grounded in evidence, integrity and compliance, and the pursuit of excellence.

Read the company’s annual report

Company Milestones

  1. Founded in Shanghai

    Junshi Biosciences was founded in Shanghai.

  2. First marketing approval

    Toripalimab received its first marketing approval in China, for previously treated advanced melanoma.

  3. US FDA approval

    The US FDA approved toripalimab-tpzi for two adult nasopharyngeal carcinoma treatment settings.

    Read the FDA decision
  4. European authorization

    The European Commission authorized Loqtorzi for specified indications in nasopharyngeal and esophageal squamous cell carcinoma.

    Read the European public assessment report

Global Presence

Toripalimab has received marketing approval in more than 50 countries and regions. Explore the markets identified in our disclosures and our research and manufacturing sites in eastern China.

Market coverage

50+ countries and regions

Highlighted markets have granted marketing approval for toripalimab.

View markets by region
Americas
Brazil, Canada, Peru, United States
Asia Pacific
Australia, Chinese mainland, Hong Kong SAR (China), India, Malaysia, Pakistan, Singapore, Thailand, Vietnam
Europe
Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom
Middle East & Africa
Bahrain, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, South Africa, United Arab Emirates
2026 interim report